VEGF TRAP FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 多发性骨髓瘤(MM)是一种浆细胞恶性克隆性增殖，其特征是单一免疫球蛋白亚型(M蛋白)的过度产生。我们的团队是最早提出MM基本病理生理学的统一概念之一。这个模型认为恶性浆细胞不能通过凋亡来经历细胞死亡。血管内皮生长因子是一种由组织产生的刺激血管生成的分子。肿瘤产生的血管内皮生长因子是肿瘤血管形成所必需的，因此，肿瘤的生存和生长也是必需的。血管内皮生长因子。血管内皮生长因子陷阱是一种血管内皮生长因子信号的长效抑制因子，它能有效地结合和失活血管内皮生长因子，从而在癌症动物模型和患有各种癌症的人类中阻断肿瘤血管的生成和生长。本研究的目的是评价血管内皮生长因子诱导剂治疗难治性或复发性多发性骨髓瘤的安全性和有效性，并进行相关研究，以评价血管内皮生长因子诱导剂治疗过程中患者组织的血管生成特性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Multiple Myeloma (MM) is a malignant clonal proliferation of plasma cells characterized by the excessive production of a single immunoglobulin protein isotype (M-protein). Our group was one of the first to propose a unified concept for the underlying pathophysiology of MM. This model proposes that malignant plasma cells fail to undergo cell death through apoptosis. VEGF is a molecule produced by tissues to stimulate angiogenesis. VEGF production by tumors is required for the vascularization, and thus, the survival and growth of tumors. VEGF. The VEGF Trap, a long-acting inhibitor of VEGF signaling, potently binds and inactivates VEGF, thus blocking tumor angiogenesis and growth in both animal models of cancer and in humans with a variety of cancers. The purpose of this study is to evaluate the safety and efficacy of VEGF Trap in patients with refractory or relapsed multiple myeloma (MM) and to perform correlative studies in order to evaluate the angiogenic properties of tissue from patients during the course of treatment with VEGF Trap.